查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1317647

肺癌免疫检查点抑制剂市场：按产品类型、最终用户划分 - 全球预测 2023-2030

Immune Checkpoint Inhibitors for Lung Cancer Market by Products, Type, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肺癌免疫检查点抑制剂的全球市场预计到2023年将达到101549万美元，复合年增长率为14.46%，预计到2030年将大幅增长达到262880万美元。我是。

FPNV定位矩阵

FPNV定位矩阵对于评估全球肺癌免疫检查点抑制剂市场至关重要。透过检视业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使用户能够根据自己的具体需求做出资讯的决策。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.肺癌免疫检查点抑制剂全球市场规模及预测为何？

2.在预测期内，COVID-19对全球肺癌免疫检查点抑制剂市场的阻碍因素和影响为何？

3. 在预测期内，全球肺癌免疫检查点抑制剂市场需要投资哪些产品/细分市场/应用/领域？

4.肺癌免疫检查点抑制剂全球市场的竞争策略为何？

5.肺癌免疫检查点抑制剂全球市场的技术趋势和法律规范如何？

6.全球肺癌免疫检查点抑制剂市场主要厂商的市占率是多少？

7. 哪些型态和策略性措施被认为适合进入肺癌免疫检查点抑制剂全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 肺癌高罹患率需要免疫检查点抑制剂
      • 政府对癌症研究和治疗的投资
      • 法规产品核可增加
    • 抑制因素
      • 免疫检查点抑制剂治疗的负担和报销是有限的
    • 机会
      • 开髮用于免疫检查点抑制剂治疗的有前景的预测生物标记
      • 将免疫检查点抑制剂与其他癌症治疗方法结合
    • 任务
      • 检查点抑制剂缺乏研究标准化
      • 免疫检查点抑制剂可能的副作用
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章肺癌免疫检查点抑制剂市场：副产品

  • 阿替利珠单抗
  • 度瓦鲁单抗
  • 纳武单抗
  • 帕博利珠单抗

第7章肺癌免疫检查点抑制剂市场：按类型

  • CTLA-4抑制剂
  • PD-1抑制剂
  • PD-L1抑制剂

第8章肺癌免疫检查点抑制剂市场：依最终用户分类

  • 学术研究所
  • 医院
  • 製药和生物技术公司

第9章美洲肺癌免疫检查点抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区肺癌免疫检查点抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲肺癌免疫检查点抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-E40E525C3821

The Global Immune Checkpoint Inhibitors for Lung Cancer Market is forecasted to grow significantly, with a projected USD 1,015.49 million in 2023 at a CAGR of 14.46% and expected to reach a staggering USD 2,628.80 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Immune Checkpoint Inhibitors for Lung Cancer Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Immune Checkpoint Inhibitors for Lung Cancer Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Products, market is studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Durvalumab is projected to witness significant market share during forecast period.

Based on Type, market is studied across CTLA-4 Inhibitors, PD-1 Inhibitors, and PD-L1 Inhibitors. The CTLA-4 Inhibitors is projected to witness significant market share during forecast period.

Based on End-Users, market is studied across Academic & Research Institutes, Hospitals, and Pharmaceutical & Biotechnology Companies. The Pharmaceutical & Biotechnology Companies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Immune Checkpoint Inhibitors for Lung Cancer Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Immune Checkpoint Inhibitors for Lung Cancer Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

4. What is the competitive strategic window for opportunities in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

5. What are the technology trends and regulatory frameworks in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

6. What is the market share of the leading vendors in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

7. What modes and strategic moves are considered suitable for entering the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products, 2022 vs 2030
  • 4.3. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type, 2022 vs 2030
  • 4.4. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users, 2022 vs 2030
  • 4.5. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
      • 5.1.1.2. Government investment in cancer research and treatment
      • 5.1.1.3. Increasing product approval by regulatory agencies
    • 5.1.2. Restraints
      • 5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
      • 5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of research standardization of checkpoint inhibitors
      • 5.1.4.2. Possible side-effects of immune checkpoint inhibitors
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products

  • 6.1. Introduction
  • 6.2. Atezolizumab
  • 6.3. Durvalumab
  • 6.4. Nivolumab
  • 6.5. Pembrolizumab

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type

  • 7.1. Introduction
  • 7.2. CTLA-4 Inhibitors
  • 7.3. PD-1 Inhibitors
  • 7.4. PD-L1 Inhibitors

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals
  • 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2022 VS 2030
  • FIGURE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2022 VS 2030 (%)
  • FIGURE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
  • FIGURE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET DYNAMICS
  • FIGURE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 14. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 145. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 146. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET LICENSE & PRICING